Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isradipine in Early Parkinson Disease
NCT02168842Phase 3Completed
- Sponsor
- University of Rochester
- Start
- Nov 2014
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in Parkinson's disease (PD) comparing Isradipine with Placebo (2 arms). Primary endpoints: Adjusted Mean Change in Total Unified Parkinson Disease Rating Scale (UPDRS) Score at 36 months and Adjusted Mean Change in Adjusted UPDRS Score at 36 months. Started Nov 2014; status: completed.
02
Drugs
Isradipine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02168842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02168842.